Invention Grant
- Patent Title: Human antibodies to human CD20 and method of using thereof
- Patent Title (中): 人CD20的人抗体及其使用方法
-
Application No.: US12183274Application Date: 2008-07-31
-
Publication No.: US07879984B2Publication Date: 2011-02-01
- Inventor: Joel H. Martin , Li-Hsien Wang , Sean Stevens , Erin M. Allison
- Applicant: Joel H. Martin , Li-Hsien Wang , Sean Stevens , Erin M. Allison
- Applicant Address: US NY Tarrytown
- Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee Address: US NY Tarrytown
- Agent Valeta Gregg; Frank R. Cottingham
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/30
Abstract:
A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.
Public/Granted literature
- US20090035322A1 Human Antibodies to Human CD20 and Method of Using Thereof Public/Granted day:2009-02-05
Information query
